Positron emission tomography imaging of endometrial cancer using engineered Anti-EMP2 antibody fragments

Molecular Imaging and Biology

Volumn 15, Issue 1, 2013, Pages 68-78

  Fu, Maoyong ^a   Brewer, Sarah ^a   Olafsen, Tove ^a   Wu, Anna M ^a   Gordon, Lynn K ^b,c   Said, Jonathan ^a   Braun, Jonathan ^a   Wadehra, Madhuri ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JULES STEIN EYE INSTITUTE   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Copper 64; Endometrial cancer; Epithelial membrane protein 2; Minibody; PET imaging

Indexed keywords

COPPER 64; EPITHELIAL MEMBRANE PROTEIN 2; EPITHELIAL MEMBRANE PROTEIN 2 ANTIBODY; EPITHELIAL MEMBRANE PROTEIN 2 ANTIBODY TETRAXETAN CU 64; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ANTIBODY; TETRASPANIN; TETRAXETAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; CONJUGATION; CONTROLLED STUDY; ENDOMETRIUM CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR LOCALIZATION; TUMOR XENOGRAFT;

ANALYSIS OF VARIANCE; ANIMALS; CELL LINE, TUMOR; COPPER RADIOISOTOPES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROTEIN ENGINEERING; TISSUE DISTRIBUTION;

MUS;

EID: 84873084894     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0558-y     Document Type: Article

References (44)

1. Wadehra M, Natarajan S, Seligson DB et al (2006) Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer 107:90-98
2. Habeeb O, Goodglick L, Soslow RA et al (2010) Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development. Cancer 116:4718-4726
3. Fu M, Maresh EL, Soslow RA et al (2010) Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer. Clin Cancer Res 16:3954-3963
4. Wadehra M, Goodglick L, Braun J (2004) The tetraspan protein EMP2 modulates the surface expression of caveolins and glycosylphosphatidyl inositol-linked proteins. Mol Biol Cell 15:2073-2083
5. Forbes A, Wadehra M, Mareninov S et al (2007) The tetraspan protein EMP2 regulates expression of caveolin-1. J Biol Chem 282:26542-26551
6. Morales SA, Mareninov S, Wadehra M et al (2009) FAK activation and the role of epithelial membrane protein 2 (EMP2) in collagen gel contraction. Invest Ophthalmol Vis Sci 50:462-469
7. Wadehra M, Forbes A, Pushkarna N et al (2005) Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium. Dev Biol 287:336-345
8. Fu M, Rao R, Sudhakar D et al (2011) Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PLoS One 6:e19945
9. Berditchevski F (2001) Complexes of tetraspanins with integrins: more than meets the eye. J Cell Sci 114:4143-4151
10. Levy S, Shoham T (2005) The tetraspanin web modulates immune-signalling complexes. Nat Rev Immunol 5:136-148
11. Maecker HT, Todd SC, Levy S (1997) The tetraspanin superfamily: molecular facilitators. FASEB J 11:428-442
12. Zevian S, Winterwood NE, Stipp CS (2011) Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by alpha3beta1 versus alpha6beta4 integrin. J Biol Chem 286:7496-7506
13. Shimazaki K, Lepin EJ, Wei B et al (2008) Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines. Clin Cancer Res 14:7367-7377
14. Czernin J, Phelps ME (2002) Positron emission tomography scanning: current and future applications. Annu Rev Med 53:89-112
15. Gambhir SS (2002) Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2:683-693
16. Stahl A, Wieder H, Piert M, Wester HJ, Senekowitsch-Schmidtke R, Schwaiger M (2004) Positron emission tomography as a tool for translational research in oncology. Mol Imaging Biol 6:214-224
17. Dumont RA, Hildebrandt I, Su H et al (2009) Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib. Cancer Res 69:3173-3179
18. Lai CH, Yen TC, Chang TC (2007) Positron emission tomography imaging for gynecologic malignancy. Curr Opin Obstet Gynecol 19:37-41
19. Schoder H, Larson SM (2004) Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 34:274-292
20. Olafsen T, Kenanova VE, Wu AM (2010) Generation of single-chain Fv fragments and multivalent derivatives scFv-Fc and scFv-CH3 (minibodies). In: Kontermann R, Dübel S (eds) Antibody engineering, vol 2. Springer, Berlin, pp 69-84
21. Olafsen T, Kenanova VE, Wu AM (2006) Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 1:2048-2060
22. Wadehra M, Sulur GG, Braun J, Gordon LK, Goodglick L (2003) Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol 74:106-112
23. Wadehra M, Dayal M, Mainigi M et al (2006) Knockdown of the tetraspan protein epithelial membrane protein-2 inhibits implantation in the mouse. Dev Biol 292:430-441
24. Lewis MR, Kao JY, Anderson AL, Shively JE, Raubitschek A (2001) An improved method for conjugating monoclonal antibodies with N- hydroxysulfosuccinimidyl DOTA. Bioconjug Chem 12:320-324
25. Olafsen T, Betting D, Kenanova VE et al (2009) Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas. J Nucl Med 50:1500-1508
26. Defrise M, Kinahan PE, Townsend DW, Michel C, Sibomana M, Newport DF (1997) Exact and approximate rebinning algorithms for 3-D PET data. IEEE Trans Med Imaging 16:145-158
27. Loening AM, Gambhir SS (2003) AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging 2:131-137
28. Ben-Porath I, Kozak CA, Benvenisty N (1998) Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22. Genomics 49:443-447
29. Wang CX, Wadehra M, Fisk BC, Goodglick L, Braun J (2001) Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood 97:3890-3895
30. Wadehra M, Mainigi M, Morales SA et al (2008) Steroid hormone regulation of EMP2 expression and localization in the endometrium. Reprod Biol Endocrinol 6:15
31. McCabe KE, Wu AM (2010) Positive progress in immunoPET - not just a coincidence. Cancer Biother Radiopharm 25:253-261
32. Wong JY, Chu DZ, Williams LE et al (2004) Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer. Clin Cancer Res 10:5014-5021
33. Sunada H, Magun BE, Mendelsohn J, MacLeod CL (1986) Monoclonal antibody against epidermal growth factor receptor is internalized without stimulating receptor phosphorylation. Proc Natl Acad Sci USA 83:3825-3829
34. Barat B, Kenanova VE, Olafsen T, Wu AM (2011) Evaluation of two internalizing carcinoembryonic antigen reporter genes for molecular imaging. Mol Imaging Biol 13:526-535
35. Shokeen M, Anderson CJ (2009) Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 42:832-841
36. Nayak TK, Brechbiel MW (2009) Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem 20:825-841
37. Wu AM, Yazaki PJ, Tsai S et al (2000) High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci USA 97:8495-8500
38. Niu G, Li Z, Cao Q, Chen X (2009) Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab. Eur J Nucl Med Mol Imaging 36:1510-1519
39. Elsasser-Beile U, Reischl G, Wiehr S et al (2009) PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J Nucl Med 50:606-611
40. Boswell CA, Sun X, Niu W et al (2004) Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 47:1465-1474
41. Sprague JE, Peng Y, Fiamengo AL et al (2007) Synthesis, characterization and in vivo studies of Cu(II)-64-labeled cross-bridged tetraazamacrocycle-amide complexes as models of peptide conjugate imaging agents. J Med Chem 50:2527-2535
42. Prasanphanich AF, Nanda PK, Rold TL et al (2007) [64Cu-NOTA-8-Aoc-BBN(7- 14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci USA 104:12462-12467
43. Prasanphanich AF, Retzloff L, Lane SR et al (2009) In vitro and in vivo analysis of [(64)Cu-NO2A-8-Aoc-BBN(7-14)NH(2)]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 36:171-181
44. Dahlin K, Mager EM, Allen L et al (2004) Identification of genes differentially expressed in rat alveolar type I cells. Am J Respir Cell Mol Biol 31:309-316